Deal Law Wire

FEBRUARY 9, 2021

Public companies involved in or procuring M&A opportunities need to be aware of the potential value and volatility that has emerged due to the rise of retail investors in both negotiating the deal and communicating its details to the public. Private Companies.

Retail 40

Retail Investors M&A Negotiation 40

Cooley M&A

APRIL 5, 2024

Pending any legislative changes, these decisions and the rationale provided by the Delaware courts illustrate the value of grounding M&A processes in statutory requirements – and offer insights into how Delaware courts evaluate governance arrangements. Moelis & Company ( Del. 1] In the ruling, Vice Chancellor J.

M&A 52

M&A Mergers and Acquisitions Mergers Corporation 52

Cooley M&A

MARCH 22, 2023

With the US initial public offering markets continuing to remain largely closed, and special purpose acquisition company combinations being costly and complex, there’s a new kid in town for foreign companies looking to go public in the US: reverse mergers.

Mergers 52

Mergers IT Mergers and Acquisitions IPO 52

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 25, 2023

The rules are expected to increase the frequency of proxy contests (particularly by less-established activists), afford dissidents increased leverage in settlement negotiations, and increase focus on the strength and qualifications of individual directors.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. Indeed, while several deals drew extended reviews, multiple other large life sciences transactions cleared Hart-Scott-Rodino review with limited to no scrutiny.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64